Tabelecleucel is a medication that uses Epstein-Barr virus (EBV)-specific allogeneic cytotoxic T cells to treat EBV-associated post-transplant lymphoproliferative disorder. It is produced by mixing T-cells with B-cells that have been infected with the Epstein-Barr virus (EBV).
- Mechanism
- Curator reviewed · 4 references
Human B cells are the main targets of Epstein-Barr virus (EBV). In immunocompetent people, EBV usually has mild effects, but in immunocompromised patients, an EBV infection can lead to potentially life-threatening consequences. For instance, patients that have gone through solid organ or bone marrow transplantation may develop EBV-associated post-transplant lymphoproliferative disorder (PTLD), a type of cancer or lymphoma caused by an uncontrolled growth of cells in lymph nodes and other organs. Tabelecleucel consists of EBV-specific allogeneic cytotoxic T cells (CTLs) that specifically target EBV-infected B-cells, helping to control EBV-associated cancers.
- First approval
- European Union, 2023
- Also known as
- EBV-CTL
- Code names
- ATA-129
- Brand names
Resolves to
What you can answer from here — as of January 17, 2025
Which companies are running trials of Tabelecleucel, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account